Darwin Discovery Limited

Ucb Pharma, S.a.

Chiroscience, Ltd.

Verity Margaret Sabin

Hazel Joan Dyke

Andrew Sharpe

Alan Findlay Haughan

George Martin Buckley

John Gary Montana

Christopher Lowe

Richard John Davenport

Hannah Jayne Kendall

Andrew Douglas Baxter

David Alan Owen

Robert John Watson

Stephen Robert Mack

Marianna Dilani Richard

Duncan Batty

Trevor Morgan

Graham John Warrellow

Rikki Peter Alexander

Roland W Bürli

Helen Tracey Horsley

Richard Jeremy Franklin

Daniel Rees Allen

Anne Marie Foley

Andrew James Ratcliffe

Duncan Robert Hannah

Karen Viviane Lucile Crépy

William Ross Pitt

Pavandeep Singh Aujla

Christopher James Lock

Karen Ann Runcie

Natasha Kinsella

Laura Jane Tait

Kerry Jenkins

John Richard Davenport

Louise Picken

Catherine Louise Picken

Sophie Caroline Williams

Benjamin Garfield Perry

David Jonathan Phillips

Patrick Marie Ghislain Pasau

Bénédicte Irma Léonce Frédérique Lallemand

William Mark Jones

A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions, said substituted derivatives having the general formula 

Quinoxaline and quinoline derivatives as kinase inhibitors

A series of 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

Fused thiazole derivatives as kinase inhibitors

A series of 5,5-dimethyl-5,6-dihydro-1,3-benzothiazol-7(4H)-one and 7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted benzofused morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I). 

Hydroxamic and carboxylic acid derivatives

Heterocyclic compounds and their therapeutic use

Compounds that are inhibitors of phosphodiesterase and have therapeutic utility, are of formula (i)

Benzothiazole compounds and their therapeutic use

Compounds of the formula ##STR1## have therapeutic utility, as inhibitors of phosphodiesterase IV and TNF release.

Quinolines and their therapeutic use

A compound of formula (i) ##STR1## has therapeutic utility via inhibition of phosphodiesterase and THF release.

Benzofuran-4-carboxamides and their therapeutic use

The subject invention concerns novel compounds of the general formula (i) ##STR1## that are useful in treating disease states, such as those states associated with proteins that mediate cellular activity. The compounds of the subject invention can be used, for example, to inhibit tumor necrosis factor and/or phosphodiesterase IV, The subject invention also concerns methods for treating disease states using the compounds of the invention.

Quinoline carboxanides and their therapeutic use

Growing community of inventors

Slough, United Kingdom

Verity Margaret Sabin